ArticleEuropean journal of neurology2025
Individual Alpha Frequency as an EEG Biomarker of Drug-Related Cognitive Burden in Epilepsy.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Individual Alpha Frequency as an EEG Biomarker of Drug-Related Cognitive Burden in Epilepsy.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEEG alpha rhythm is well-proven to correlate with cognitive performance in healthy subjects. We aimed to evaluate the potential of EEG background activity, quantified as individual alpha frequency (IAF), as a biomarker of cognitive impairment induced by antiseizure medications (ASMs) in people with epilepsy (PwE).
methodsWe conducted a cross-sectional study (S1) and a prospective longitudinal study (S2). In S1, PwE underwent EEG recording and concurrent EpiTrack assessment. In S2, EEG and EpiTrack were performed before and 6 months after initiating cenobamate. Correlation analyses assessed the association between EpiTrack scores and IAF (S1) and their changes post-cenobamate (S2). ANOVA and ANCOVA were used to compare IAF between cognitively impaired and unimpaired PwE. Logistic regression evaluated the incremental value of IAF combined with clinical variables to identify cognitive improvement following ASM modification.
resultsWe enrolled 100 PwE (42 ± 18 years) in S1 and 33 PwE (45 ± 15 years) in S2. IAF correlated significantly with EpiTrack scores in S1 (R = 0.21, p = 0.03), and IAF changes mirrored EpiTrack improvements post-cenobamate in S2 (R = 0.34, p = 0.04). Cognitively impaired PwE displayed significantly lower IAF independent of age, seizure frequency, epileptiform activity, and pharmacological load (p = 0.01-0.005). Adding IAF to clinical variables significantly improved the logistic model's accuracy in predicting cognitive improvement post-treatment (AUC: 0.83 ± 0.04 vs. 0.71 ± 0.04, p = 0.005).
conclusionsEEG background activity, assessed via IAF, is sensitive to cognitive impairment related to ASMs in PwE, demonstrated in both cross-sectional and longitudinal contexts. IAF is thus a promising, simple, cost-effective biomarker to monitor cognitive burden in clinical epilepsy management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.